Truist raised the firm’s price target on BridgeBio (BBIO) to $80 from $66 and keeps a Buy rating on the shares. The firm has updated its model to reflect Attruby performance in Q3, positive Phase 3 data in ribitol in LGMD2I/R9, and positive Phase 3 data in encaleret in ADH1, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO: